Success Metrics

Clinical Success Rate
100.0%

Based on 1 completed trials

Completion Rate
100%(1/1)
Active Trials
1(25%)
Results Posted
0%(0 trials)

Phase Distribution

Ph not_applicable
1
25%
Ph phase_4
1
25%
Ph phase_2
2
50%

Phase Distribution

0

Early Stage

2

Mid Stage

1

Late Stage

Phase Distribution4 total trials
Phase 2Efficacy & side effects
2(50.0%)
Phase 4Post-market surveillance
1(25.0%)
N/ANon-phased studies
1(25.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

1 of 1 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

4

all time

Status Distribution
Active(1)
Completed(1)
Other(2)

Detailed Status

unknown2
Recruiting1
Completed1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
1
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 22 (50.0%)
Phase 41 (25.0%)
N/A1 (25.0%)

Trials by Status

recruiting125%
completed125%
unknown250%

Recent Activity

1 active trials
Showing 4 of 4
recruitingnot_applicable

Novel Skin Barrier Product Versus Petrolatum for Skin Barrier Dysfunction

NCT07183423
unknownphase_2

Efficacy of Tazarotene in Treatment of Verruca Plana

NCT05314127
unknownphase_2

Turmeric Based Therapy in the Treatment of Psoriasis: A Clinical Trial

NCT04071106
completedphase_4

Clinical Trial of 0.0003% Calcitriol, 0.1% Tacrolimus, and Petrolatum for the Treatment of Pityriasis Alba

NCT01388517

Clinical Trials (4)

Showing 4 of 4 trials
NCT07183423Not Applicable

Novel Skin Barrier Product Versus Petrolatum for Skin Barrier Dysfunction

Recruiting
NCT05314127Phase 2

Efficacy of Tazarotene in Treatment of Verruca Plana

Unknown
NCT04071106Phase 2

Turmeric Based Therapy in the Treatment of Psoriasis: A Clinical Trial

Unknown
NCT01388517Phase 4

Clinical Trial of 0.0003% Calcitriol, 0.1% Tacrolimus, and Petrolatum for the Treatment of Pityriasis Alba

Completed

All 4 trials loaded

Drug Details

Intervention Type
OTHER
Total Trials
4